Synergistic activation of the tumor suppressor, HLJ1, by the transcription factors YY1 and activator protein 1

Chi Chung Wang, Meng Feng Tsai, Ting Hao Dai, Tse-Ming Hong, Wing Kai Chan, Jeremy J.W. Chen, Pan Chyr Yang

研究成果: Article

40 引文 (Scopus)

摘要

HLJ1 is a novel tumor and invasion suppressor that inhibits tumorigenesis and cancer metastasis. However, the mechanism of HLJ1 activation is currently unclear. Here, we identify an enhancer segment in the HLJ1 gene at -2,125 to -1,039 bp upstream of the transcription start site. A 50-bp element between -1,492 and -1,443 bp is the minimal enhancer segment, which includes the activator protein 1 (AP-1) site (-1,457 to -1,451 bp), an essential regulatory domain that binds the transcriptional factors FosB, JunB, and JunD. Chromatin immunoprecipitation assays confirm that these AP-1 family members bind to a specific site in the HLJ1 enhancer segment in vivo. Overexpression of either YY1 at promoter or AP-1 at enhancer results in a 3-fold increase in the transcriptional activity of HLJ1. We propose a novel mechanism whereby expression of the tumor suppressor, HLJ1, is upregulated via enhancer AP-1 binding to promoter YY1 and the coactivator, p300, through DNA bending and multiprotein complex formation. The combined expression of AP-1 and YY1 enhances HLJ1 expression by more than five times and inhibits in vitro cancer cell invasion. Elucidation of the regulatory mechanism of HLJ1 expression may facilitate the development of personalized therapy by inhibiting cancer cell proliferation, angiogenesis, and metastasis.

原文English
頁(從 - 到)4816-4826
頁數11
期刊Cancer Research
67
發行號10
DOIs
出版狀態Published - 2007 五月 15

指紋

YY1 Transcription Factor
Transcription Factor AP-1
Neoplasms
Neoplasm Metastasis
Multiprotein Complexes
Chromatin Immunoprecipitation
Transcription Initiation Site
Protein Binding
Carcinogenesis
Cell Proliferation
DNA
Genes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

引用此文

Wang, Chi Chung ; Tsai, Meng Feng ; Dai, Ting Hao ; Hong, Tse-Ming ; Chan, Wing Kai ; Chen, Jeremy J.W. ; Yang, Pan Chyr. / Synergistic activation of the tumor suppressor, HLJ1, by the transcription factors YY1 and activator protein 1. 於: Cancer Research. 2007 ; 卷 67, 編號 10. 頁 4816-4826.
@article{4543aa41c69a437f84637104dfec63d7,
title = "Synergistic activation of the tumor suppressor, HLJ1, by the transcription factors YY1 and activator protein 1",
abstract = "HLJ1 is a novel tumor and invasion suppressor that inhibits tumorigenesis and cancer metastasis. However, the mechanism of HLJ1 activation is currently unclear. Here, we identify an enhancer segment in the HLJ1 gene at -2,125 to -1,039 bp upstream of the transcription start site. A 50-bp element between -1,492 and -1,443 bp is the minimal enhancer segment, which includes the activator protein 1 (AP-1) site (-1,457 to -1,451 bp), an essential regulatory domain that binds the transcriptional factors FosB, JunB, and JunD. Chromatin immunoprecipitation assays confirm that these AP-1 family members bind to a specific site in the HLJ1 enhancer segment in vivo. Overexpression of either YY1 at promoter or AP-1 at enhancer results in a 3-fold increase in the transcriptional activity of HLJ1. We propose a novel mechanism whereby expression of the tumor suppressor, HLJ1, is upregulated via enhancer AP-1 binding to promoter YY1 and the coactivator, p300, through DNA bending and multiprotein complex formation. The combined expression of AP-1 and YY1 enhances HLJ1 expression by more than five times and inhibits in vitro cancer cell invasion. Elucidation of the regulatory mechanism of HLJ1 expression may facilitate the development of personalized therapy by inhibiting cancer cell proliferation, angiogenesis, and metastasis.",
author = "Wang, {Chi Chung} and Tsai, {Meng Feng} and Dai, {Ting Hao} and Tse-Ming Hong and Chan, {Wing Kai} and Chen, {Jeremy J.W.} and Yang, {Pan Chyr}",
year = "2007",
month = "5",
day = "15",
doi = "10.1158/0008-5472.CAN-07-0504",
language = "English",
volume = "67",
pages = "4816--4826",
journal = "Cancer Research",
issn = "0008-5472",
number = "10",

}

Synergistic activation of the tumor suppressor, HLJ1, by the transcription factors YY1 and activator protein 1. / Wang, Chi Chung; Tsai, Meng Feng; Dai, Ting Hao; Hong, Tse-Ming; Chan, Wing Kai; Chen, Jeremy J.W.; Yang, Pan Chyr.

於: Cancer Research, 卷 67, 編號 10, 15.05.2007, p. 4816-4826.

研究成果: Article

TY - JOUR

T1 - Synergistic activation of the tumor suppressor, HLJ1, by the transcription factors YY1 and activator protein 1

AU - Wang, Chi Chung

AU - Tsai, Meng Feng

AU - Dai, Ting Hao

AU - Hong, Tse-Ming

AU - Chan, Wing Kai

AU - Chen, Jeremy J.W.

AU - Yang, Pan Chyr

PY - 2007/5/15

Y1 - 2007/5/15

N2 - HLJ1 is a novel tumor and invasion suppressor that inhibits tumorigenesis and cancer metastasis. However, the mechanism of HLJ1 activation is currently unclear. Here, we identify an enhancer segment in the HLJ1 gene at -2,125 to -1,039 bp upstream of the transcription start site. A 50-bp element between -1,492 and -1,443 bp is the minimal enhancer segment, which includes the activator protein 1 (AP-1) site (-1,457 to -1,451 bp), an essential regulatory domain that binds the transcriptional factors FosB, JunB, and JunD. Chromatin immunoprecipitation assays confirm that these AP-1 family members bind to a specific site in the HLJ1 enhancer segment in vivo. Overexpression of either YY1 at promoter or AP-1 at enhancer results in a 3-fold increase in the transcriptional activity of HLJ1. We propose a novel mechanism whereby expression of the tumor suppressor, HLJ1, is upregulated via enhancer AP-1 binding to promoter YY1 and the coactivator, p300, through DNA bending and multiprotein complex formation. The combined expression of AP-1 and YY1 enhances HLJ1 expression by more than five times and inhibits in vitro cancer cell invasion. Elucidation of the regulatory mechanism of HLJ1 expression may facilitate the development of personalized therapy by inhibiting cancer cell proliferation, angiogenesis, and metastasis.

AB - HLJ1 is a novel tumor and invasion suppressor that inhibits tumorigenesis and cancer metastasis. However, the mechanism of HLJ1 activation is currently unclear. Here, we identify an enhancer segment in the HLJ1 gene at -2,125 to -1,039 bp upstream of the transcription start site. A 50-bp element between -1,492 and -1,443 bp is the minimal enhancer segment, which includes the activator protein 1 (AP-1) site (-1,457 to -1,451 bp), an essential regulatory domain that binds the transcriptional factors FosB, JunB, and JunD. Chromatin immunoprecipitation assays confirm that these AP-1 family members bind to a specific site in the HLJ1 enhancer segment in vivo. Overexpression of either YY1 at promoter or AP-1 at enhancer results in a 3-fold increase in the transcriptional activity of HLJ1. We propose a novel mechanism whereby expression of the tumor suppressor, HLJ1, is upregulated via enhancer AP-1 binding to promoter YY1 and the coactivator, p300, through DNA bending and multiprotein complex formation. The combined expression of AP-1 and YY1 enhances HLJ1 expression by more than five times and inhibits in vitro cancer cell invasion. Elucidation of the regulatory mechanism of HLJ1 expression may facilitate the development of personalized therapy by inhibiting cancer cell proliferation, angiogenesis, and metastasis.

UR - http://www.scopus.com/inward/record.url?scp=34250376736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250376736&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-07-0504

DO - 10.1158/0008-5472.CAN-07-0504

M3 - Article

C2 - 17510411

AN - SCOPUS:34250376736

VL - 67

SP - 4816

EP - 4826

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 10

ER -